A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1 ... in studies up to 52 weeks. Also in combination with metformin and ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 inhibitors ... [1] In the presence of elevated glucose concentrations, GLP-1 and GIP increase ...

A collaboration between a drug plan and clinical pharmacists led to nearly 50% of members successfully switching to a preferred dipeptidyl-peptidase-4 inhibitor.

once-daily GLP-1 agonist liraglutide. Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025 ...

In terms of new products, both Novo Nordisk and Sanofi are set to launch basal insulin/GLP-1 combinations ... 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos ...

in combination with semaglutide, a GLP-1 agonist marketed by Novo Nordisk (NYSE: NVO) un As the U.S. markets experience mixed results with the S&P 500 and Dow Jones snapping their six-week winning ...

Eli Lilly is joining in a lawsuit filed by the Outsourcing Facilities against the FDA, aiming to reverse the FDA's October 2024 determination that the shortage has been resolved, which would allow ...